Delivery Order SPE2DR25D2005-SPE2DR26FE7A6
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $6,133.96 to AmerisourceBergen Drug Corp for Eliquis 5 mg tablets (60-count packages), with an ultimate completion date of August 14, 2025. This non-competitive, firm fixed-price delivery order was issued under a larger Indefinite Delivery Contract (IDC) vehicle—specifically the DLA Troop Support Medical SPE2DX prime vendor contract valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) valued at $16,636.35 under a firm fixed-price contract. The award was made on August 25, 2025, with an ultimate completion date of August 26, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the delivery of this pharmaceutical product from its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $16,498.12 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count) on November 12, 2025, with completion expected by November 13, 2025. This non-competitive, firm fixed-price delivery order represents a routine pharmaceutical procurement to support military healthcare operations. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Eliquis 5 mg tablets (60-count packages) valued at $25,897.33. This non-set-aside, competitively awarded contract represents a firm fixed-price delivery order with an ultimate completion date of July 25, 2025. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $6,797.30 to AmerisourceBergen Drug Corp for 60 tablets of Eliquis 5 mg, with an ultimate completion date of April 25, 2025. This competitive award uses firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $5,011.15 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) on June 2, 2025, with an ultimate completion date of June 3, 2025. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract with performance executed from the contractor's Conshohocken, Pennsylvania facility. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count) under a firm fixed-price contract with a ceiling value of $25,462.14. The delivery order, awarded November 4, 2025, with an ultimate completion date of November 5, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, executed the order from its corporate office location, serving as the prime...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) under a firm fixed-price contract valued at $25,599.93, with an ultimate completion date of July 15, 2025. This non-set-aside, competitively awarded delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order valued at $6,283.59 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count) on August 6, 2025, with ultimate completion scheduled for August 7, 2025. This non-competitive delivery order utilizes firm fixed price terms and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December...
- The Defense Logistics Agency awarded a delivery order valued at $22,298.21 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) under a firm fixed price contract. The award, issued on November 7, 2025, with an ultimate completion date of November 10, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken,...
- SPE2DR25D2005Indefinite Delivery Contract
- SPE2DR25D2005-SPE2DR26FE7A6Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count) at a firm fixed price of $6,127.65, with an ultimate completion date of November 19, 2025. This non-set-aside, competitively awarded contract reflects AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal medical procurement needs. The award is issued as a delivery order under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a total value of $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major vendor for the Defense Health Agency and other government healthcare systems, supplying an extensive portfolio of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains. This particular delivery order for Eliquis—an anticoagulant medication used for stroke prevention and blood clot treatment—represents one of numerous pharmaceutical supply orders the company fulfills under its comprehensive prime vendor agreement with DLA, which enables the company to support military healthcare programs globally with flexible, efficient medical supply procurement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.1k | 11/18/25 |